Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Mazor, Yariv ^a   Sachsenmeier, Kris F ^a   Yang, Chunning ^a   Hansen, Anna ^a   Filderman, Jessica ^a   Mulgrew, Kathy ^a   Wu, Herren ^a   Dall'Acqua, William F ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TRASTUZUMAB;

ANIMAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; DRUG SCREENING; HUMAN; IMMUNOLOGY; NON SMALL CELL LUNG CANCER; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; HUMANS; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRASTUZUMAB; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85008940862     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep40098     Document Type: Article

References (51)

1. Reichert, J. M. Antibodies to watch in 2016. MAbs 8, 197-204, doi: 10. 1080/19420862. 2015. 1125583 (2016).
2. Carter, P. J. Potent antibody therapeutics by design. Nat Rev Immunol 6, 343-357, doi: 10. 1038/nri1837 (2006).
3. Nelson, A. L., Dhimolea, E. & Reichert, J. M. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9, 767-774, doi: 10. 1038/nrd3229 (2010).
4. Reichert, J. M. & Dhimolea, E. The future of antibodies as cancer drugs. Drug discovery today 17, 954-963, doi: 10. 1016/j. drudis. 2012. 04. 006 (2012).
5. Chan, A. C. & Carter, P. J. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10, 301-316, doi: 10. 1038/ nri2761 (2010).
6. Alexander, S. & Friedl, P. Cancer invasion and resistance: interconnected processes of disease progression and therapy failure. Trends Mol Med 18, 13-26, doi: 10. 1016/j. molmed. 2011. 11. 003 (2012).
7. Fitzgerald, J. & Lugovskoy, A. Rational engineering of antibody therapeutics targeting multiple oncogene pathways. MAbs 3, 299-309 (2011).
8. Petrelli, A. & Giordano, S. From single-to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 15, 422-432 (2008).
9. Scott, A. M., Wolchok, J. D. & Old, L. J. Antibody therapy of cancer. Nature reviews. Cancer 12, 278-287, doi: 10. 1038/nrc3236 (2012).
10. Thakur, A. & Lum, L. G. Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther 12, 340-349 (2010).
11. Kontermann, R. E. & Brinkmann, U. Bispecific antibodies. Drug discovery today 20, 838-847, doi: 10. 1016/j. drudis. 2015. 02. 008 (2015).
12. Spiess, C., Zhai, Q. & Carter, P. J. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 67, 95-106, doi: 10. 1016/j. molimm. 2015. 01. 003 (2015).
13. Rudnick, S. I. & Adams, G. P. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm 24, 155-161, doi: 10. 1089/cbr. 2009. 0627 (2009).
14. Zheng, S. et al. Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody. MAbs 8, 551-561, doi: 10. 1080/19420862. 2015. 1136762 (2016).
15. Schubert, I. et al. A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells. MAbs 6, 286-296, doi: 10. 4161/mabs. 26768 (2014).
16. Harms, B. D., Kearns, J. D., Iadevaia, S. & Lugovskoy, A. A. Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies. Methods 65, 95-104, doi: 10. 1016/j. ymeth. 2013. 07. 017 (2014).
17. Lu, D. et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulinlike growth factor receptor for enhanced antitumor activity. J Biol Chem 280, 19665-19672, doi: 10. 1074/jbc. M500815200 (2005).
18. Robinson, M. K. et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 99, 1415-1425, doi: 10. 1038/sj. bjc. 6604700 (2008).
19. Jarantow, S. W. et al. Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor x c-MET Bispecific Antibody. Journal of Biological Chemistry 290, 24689-24704, doi: 10. 1074/jbc. M115. 651653 (2015).
20. Mazor, Y. et al. Insights into the molecular basis of a bispecific antibody's target selectivity. MAbs 7, 461-469, doi: 10. 1080/19420862. 2015. 1022695 (2015).
21. Terrett JA, L. L., John King, D., Cardarelli, J. M., Pan, C., Huang, H. & Coccia, M. A. Human monoclonal antibodies to cd70. (2006).
22. Burkly, L. C. et al. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. Journal of immunology 149, 1779-1787 (1992).
23. Carter, P. et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89, 4285-4289 (1992).
24. Gerdes, C. A. et al. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res 19, 1126-1138, doi: 10. 1158/1078-0432. CCR-12-0989 (2013).
25. Coloma, M. J. & Morrison, S. L. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 15, 159-163, doi: 10. 1038/nbt0297-159 (1997).
26. Mazor, Y. et al. Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs 7, 377-389, doi: 10. 1080/19420862. 2015. 1007816 (2015).
27. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823, doi: 10. 1126/science. 1231143 (2013).
28. Schubert, I. et al. A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen doublepositive cells by dual-targeting. MAbs 4, 45-56, doi: 10. 4161/mabs. 4. 1. 18498 (2012).
29. Mazor, Y. et al. Enhancement of Immune Effector Functions by Modulating IgG's Intrinsic Affinity for Target Antigen. PLoS One 11, e0157788, doi: 10. 1371/journal. pone. 0157788 (2016).
30. Vauquelin, G. & Charlton, S. J. Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands. Br J Pharmacol 168, 1771-1785, doi: 10. 1111/bph. 12106 (2013).
31. Castillo, L. et al. Pharmacological background of EGFR targeting. Ann Oncol 15, 1007-1012, doi: 10. 1093/annonc/mdh257 (2004).
32. Lacouture, M. E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature reviews. Cancer 6, 803-812, doi: 10. 1038/nrc1970 (2006).
33. Agero, A. L. et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55, 657-670, doi: 10. 1016/j. jaad. 2005. 10. 010 (2006).
34. Lacouture, M. E. & Rodeck, U. Skinflammation and drug toxicity-a delicate balance. Sci Transl Med 5, 199fs133, doi: 10. 1126/ scitranslmed. 3006993 (2013).
35. Fakih, M. & Vincent, M. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol 17 Suppl 1, S18-30 (2010).
36. Brown, J., Su, Y., Nelleson, D., Shankar, P. & Mayo, C. Management of epidermal growth factor receptor inhibitor-associated rash: a systematic review. J Community Support Oncol 14, 21-28, doi: 10. 12788/jcso. 0193 (2016).
37. Brabender, J. et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res 7, 1850-1855 (2001).
38. Larbouret, C. et al. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res 13, 3356-3362, doi: 10. 1158/1078-0432. CCR-06-2302 (2007).
39. Kawaguchi, Y. et al. Targeting EGFR and HER-2 with cetuximab-and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 97, 494-501, doi: 10. 1038/sj. bjc. 6603885 (2007).
40. Larbouret, C. et al. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann Oncol 21, 98-103, doi: 10. 1093/annonc/mdp496 (2010).
41. Carlsson, J., Shen, L., Xiang, J., Xu, J. & Wei, Q. Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors. Oncology letters 5, 208-214, doi: 10. 3892/ol. 2012. 996 (2013).
42. Quesnelle, K. M. & Grandis, J. R. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res 17, 5935-5944, doi: 10. 1158/1078-0432. CCR-11-0370 (2011).
43. Marvin, J. S. & Zhu, Z. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin 26, 649-658, doi: 10. 1111/j. 1745-7254. 2005. 00119. x (2005).
44. Schietinger, A., Philip, M. & Schreiber, H. Specificity in cancer immunotherapy. Seminars in immunology 20, 276-285, doi: 10. 1016/j. smim. 2008. 07. 001 (2008).
45. Olejniczak, S. H., Stewart, C. C., Donohue, K. & Czuczman, M. S. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest 35, 93-114, doi: 10. 1080/08820130500496878 (2006).
46. Supernat, A. et al. Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer. Transl Oncol 7, 613-619, doi: 10. 1016/j. Tranon. 2014. 06. 001 (2014).
47. Stahl, P. et al. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol 15, 7, doi: 10. 1186/s12876-015-0231-4 (2015).
48. Hand, P. H., Nuti, M., Colcher, D. & Schlom, J. Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumor-associated antigens. Cancer Res 43, 728-735 (1983).
49. Grada, Z. et al. TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Mol Ther Nucleic Acids 2, e105, doi: 10. 1038/mtna. 2013. 32 (2013).
50. Hegde, M. et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther 21, 2087-2101, doi: 10. 1038/mt. 2013. 185 (2013).
51. Dimasi, N. et al. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. Journal of molecular biology 393, 672-692, doi: 10. 1016/j. jmb. 2009. 08. 032 (2009).